Evidence map›Paper›PMID 21768102›Full record

ArticleThe Journal of biological chemistry2011

The auto-ubiquitylation of E3 ubiquitin-protein ligase Chfr at G2 phase is required for accumulation of polo-like kinase 1 and mitotic entry in mammalian cells.

Jo-Sun Kim, Yong-Yea Park, Sun-Yi Park, Hyeseon Cho, Dongmin Kang, Hyeseong Cho

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. CHFR: a key checkpoint component implicated in a wide range of cancers.Cellular and molecular life sciences : CMLS · 2012
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Jo-Sun KimDepartment of Biochemistry, Ajou University School of Medicine, Suwon 443-721 Korea; Graduate School of Molecular Science and Technology, Ajou University, Suwon 443-721 Korea.
Yong-Yea ParkDepartment of Biochemistry, Ajou University School of Medicine, Suwon 443-721 Korea; Graduate School of Molecular Science and Technology, Ajou University, Suwon 443-721 Korea.
Sun-Yi ParkDepartment of Biochemistry, Ajou University School of Medicine, Suwon 443-721 Korea; Graduate School of Molecular Science and Technology, Ajou University, Suwon 443-721 Korea.
Hyeseon ChoB Cell Molecular Immunology Section, Laboratory of Immunoregulation, National Institutes of Health, Bethesda, Maryland 20892.
Dongmin KangDepartment of Life Science, Division of Life and Pharmaceutical Sciences, and the Center for Cell Signaling and Drug Discovery Research, Ewha Womans University, Seoul 120-750, Korea.
Hyeseong ChoDepartment of Biochemistry, Ajou University School of Medicine, Suwon 443-721 Korea; Graduate School of Molecular Science and Technology, Ajou University, Suwon 443-721 Korea. Electronic address: hscho@ajou.ac.kr.
Ajou University · KRNational Institutes of Health · USEwha Womans University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The E3 ubiquitin-protein ligase Chfr is a mitotic stress checkpoint protein that delays mitotic entry in response to microtubule damage; however, the molecular mechanism by which Chfr accomplishes this remains elusive. Here, we show that Chfr levels are elevated in response to microtubule-damaging stress. Moreover, G(2)/M transition is associated with cell cycle-dependent turnover of Chfr accompanied by high autoubiquitylation activity, suggesting that regulation of Chfr levels and auto-ubiquitylation activity are functionally significant. To test this, we generated Chfr mutants Chfr-K2A and Chfr-K5A in which putative lysine target sites of auto-ubiquitylation were replaced with alanine. Chfr-K2A did not undergo cell cycle-dependent degradation, and its levels remained high during G(2)/M phase. The elevated levels of Chfr-K2A caused a significant reduction in phosphohistone H3 levels and cyclinB1/Cdk1 kinase activities, leading to mitotic entry delay. Notably, polo-like kinase 1 levels at G(2) phase, but not at S phase, were ∼2-3-fold lower in cells expressing Chfr-K2A than in wild-type Chfr-expressing cells. Consistent with this, ubiquitylation of Plk1 at G(2) phase was accelerated in Chfr-K2A-expressing cells. In contrast, Aurora A levels remained constant, indicating that Plk1 is a major target of Chfr in controlling the timing of mitotic entry. Indeed, overexpression of Plk1 in Chfr-K2A-expressing cells restored cyclin B1/Cdk1 kinase activity and promoted mitotic entry. Collectively, these data indicate that Chfr auto-ubiquitylation is required to allow Plk1 to accumulate to levels necessary for activation of cyclin B1/Cdk1 kinase and mitotic entry. Our results provide the first evidence that Chfr auto-ubiquitylation and degradation are important for the G(2)/M transition.

Indexed as

MitosisAlanineAnimalsBinding SitesCDC2 Protein KinaseCell Cycle ProteinsCyclin B1Flow CytometryG2 PhaseHeLa CellsHumansLysineModels, BiologicalNeoplasm ProteinsPolo-Like Kinase 1Poly-ADP-Ribose Binding ProteinsAlanineCDC2 Protein KinaseCell Cycle ProteinsCHFR protein, humanCyclin B1LysineNeoplasm ProteinsPolo-Like Kinase 1Poly-ADP-Ribose Binding ProteinsProtein Serine-Threonine KinasesProto-Oncogene ProteinsUbiquitinUbiquitin-Protein Ligases

Identifiers

PMID21768102
PMCPMC3162422
OpenAlexW2060557886

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.